create a website

New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses. (2012). Roberts, Melissa ; Mapel, Douglas .
In: PharmacoEconomics.
RePEc:spr:pharme:v:30:y:2012:i:10:p:869-885.

Full description at Econpapers || Download paper

Cited: 1

Citations received by this document

Cites: 137

References cited by this document

Cocites: 50

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

  1. The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients. (2014). Conti, Sara ; Mantovani, Lorenzo Giovanni ; Cesana, Giancarlo ; Blasi, Francesco ; Fornari, Carla ; Chiodini, Virginio ; Aliberti, Stefano.
    In: PLOS ONE.
    RePEc:plo:pone00:0101228.

    Full description at Econpapers || Download paper

References

References cited by this document

  1. Aaron SD, Ramsay T, Vandemheen K, et al. A threshold regression model for recurrent exacerbations in chronic obstructive pulmonary disease. J Clin Epidemiol 2010 Dec; 63 (12): 1324–31.
    Paper not yet in RePEc: Add citation now
  2. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007 Apr 17; 146 (8): 545–55.
    Paper not yet in RePEc: Add citation now
  3. Agusti A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011 Sep 1; 184 (5): 507–13.
    Paper not yet in RePEc: Add citation now
  4. Akazawa M, Halpern R, Riedel AA, et al. Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respir Med 2008 Dec; 102 (12): 1744–52.
    Paper not yet in RePEc: Add citation now
  5. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005 Feb 15; 142 (4): 233–9.
    Paper not yet in RePEc: Add citation now
  6. Ayres JG, Price MJ, Efthimiou J. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. Respir Med 2003 Mar; 97 (3): 212–20.
    Paper not yet in RePEc: Add citation now
  7. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy 2009 Aug; 29 (8): 891–905.
    Paper not yet in RePEc: Add citation now
  8. Balcells E, Anto JM, Gea J, et al. Characteristics of patients admitted for the first time for COPD exacerbation. Respir Med 2009 Sep; 103 (9): 1293–302.
    Paper not yet in RePEc: Add citation now
  9. Bartolomeo N, Trerotoli P, Moretti A, et al. A Markov model to evaluate hospital readmission. BMC Med Res Methodol 2008; 8: 23.
    Paper not yet in RePEc: Add citation now
  10. Benzo RP, Chang CC, Farrell MH, et al. Physical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary disease. Respiration 2010; 80(1): 10–8.
    Paper not yet in RePEc: Add citation now
  11. Blanc PD, Menezes AM, Plana E, et al. Occupational exposures and COPD: an ecological analysis of international data. Eur Respir J 2009 Feb; 33 (2): 298–304.
    Paper not yet in RePEc: Add citation now
  12. Borg S, Ericsson A, Wedzicha J, et al. A computer simu-lation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004 Mar–Apr; 7 (2): 153–67.
    Paper not yet in RePEc: Add citation now

  13. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006 Dec; 15 (12): 1295–310.

  14. Briggs AH, Glick HA, Lozano-Ortega G, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J 2010 Mar; 35 (3): 532–9.
    Paper not yet in RePEc: Add citation now
  15. Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S71–9.
    Paper not yet in RePEc: Add citation now
  16. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Resp J Suppl 2003 Jun; 41: 46s–53s.
    Paper not yet in RePEc: Add citation now
  17. Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010 Aug; 65 (8): 719–25.
    Paper not yet in RePEc: Add citation now
  18. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 Feb 22; 356 (8): 775–89.
    Paper not yet in RePEc: Add citation now
  19. Caro JJ, Moller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health 2010 Dec; 13 (8): 1056–60.
    Paper not yet in RePEc: Add citation now
  20. CDC. Deaths from chronic obstructive pulmonary disease: United States, 2000–2005. MMWR Morb Mortal Wkly Rep 2008 Nov 14; 57 (45): 1229–32.
    Paper not yet in RePEc: Add citation now
  21. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010 Jan; 137 (1): 20–30.
    Paper not yet in RePEc: Add citation now
  22. Celli BR. Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thorac Soc 2006; 3 (1): 58–65.
    Paper not yet in RePEc: Add citation now
  23. Celli BR. Predictors of mortality in COPD. Respir Med 2010 Jun; 104 (6): 773–9.
    Paper not yet in RePEc: Add citation now
  24. Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults: United States, 2005. MMWR Morb Mortal Wkly Rep 2009 May 1; 58 (16): 421–6.
    Paper not yet in RePEc: Add citation now
  25. Centers for Disease Control and Prevention (CDC). Smoking-attributable mortality, years of potential life lost, and productivity losses: United States, 2000–2004. MMWR Morb Mortal Wkly Rep 2008 Nov 14; 57 (45): 1226–8.
    Paper not yet in RePEc: Add citation now
  26. Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S23–31.
    Paper not yet in RePEc: Add citation now
  27. Chuck A, Jacobs P, Mayers I, et al. Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease. Can Respir J 2008 Nov–Dec; 15 (8): 437–43.
    Paper not yet in RePEc: Add citation now

  28. Cooper K, Brailsford SC, Davies R. Choice of modelling technique for evaluating health care interventions. J Oper Res Soc 2007 Feb; 58 (2): 168–76.

  29. Critical assessment of economic evaluation. In: Drummond M, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 1997: 27–51.
    Paper not yet in RePEc: Add citation now
  30. D’Souza AO, Smith MJ, Miller LA, et al. An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest 2006 Jun; 129 (6): 1693–708.
    Paper not yet in RePEc: Add citation now
  31. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S43–50.
    Paper not yet in RePEc: Add citation now
  32. Dal Negro RW, Tognella S, Tosatto R, et al. Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (Social Impact of Respiratory Integrated Outcomes). Respir Med 2008 Jan; 102 (1): 92–101.
    Paper not yet in RePEc: Add citation now
  33. Dal NR, Eandi M, Pradelli L, et al. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients. Int J Chron Obstruct Pulmon Dis 2007; 2 (2): 169–76.
    Paper not yet in RePEc: Add citation now
  34. Dalal AA, Shah M, D’Souza AO, et al. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med 2011 Mar; 105 (3): 454–60.
    Paper not yet in RePEc: Add citation now
  35. Dalal AA, Shah M, Lunacsek O, et al. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med 2011 Oct; 105 (10): 1516–22.
    Paper not yet in RePEc: Add citation now
  36. Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010 May; 137 (5): 1091–7.
    Paper not yet in RePEc: Add citation now
  37. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002 Oct; 57 (10): 847–52.
    Paper not yet in RePEc: Add citation now
  38. Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011; 6: 477–92.
    Paper not yet in RePEc: Add citation now
  39. Earnshaw SR, Wilson MR, Dalal AA, et al. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med 2009 Jan; 103 (1): 12–21.
    Paper not yet in RePEc: Add citation now
  40. Effing TW, Kerstjens HA, Monninkhof EM, et al. Definitions of exacerbations: does it really matter in clinical trials on COPD? Chest 2009 Sep; 136 (3): 918–23.
    Paper not yet in RePEc: Add citation now

  41. Eisner MD, Yelin EH, Trupin L, et al. The influence of chronic respiratory conditions on health status and work disability. Am J Public Health 2002 Sep; 92 (9): 1506–13.

  42. Ferdinands JM, Mannino DM. Obstructive lung disease models: what is valid? COPD 2008 Dec; 5 (6): 382–93.
    Paper not yet in RePEc: Add citation now
  43. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977 Jun 25; 1 (6077): 1645–8.
    Paper not yet in RePEc: Add citation now
  44. Fletcher MJ, Upton J, Taylor-Fishwick J, et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health 2011; 11: 612.
    Paper not yet in RePEc: Add citation now
  45. Foster TS, Miller JD, Marton JP, et al. Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD 2006 Dec; 3 (4): 211–8.
    Paper not yet in RePEc: Add citation now
  46. Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care 2007 Dec; 45 (12): 1162–70.
    Paper not yet in RePEc: Add citation now
  47. Gani R, Griffin J, Kelly S, et al. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010 Mar; 19 (1): 68–74.
    Paper not yet in RePEc: Add citation now
  48. Garcia-Rio F, Soriano JB, Miravitlles M, et al. Over-diagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life. Chest 2011 May; 139 (5): 1072–80.
    Paper not yet in RePEc: Add citation now
  49. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD, 2011 [online]. Available from URL: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosi s-management.html [Accessed 2012 Jan 5].
    Paper not yet in RePEc: Add citation now
  50. Goossens LM, Nivens MC, Sachs P, et al. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? Respir Med 2011 Aug; 105 (8): 1195–202.
    Paper not yet in RePEc: Add citation now
  51. Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S81–9.
    Paper not yet in RePEc: Add citation now
  52. Halpin DM. Health economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006 May; 3 (3): 227–33.
    Paper not yet in RePEc: Add citation now
  53. Hays RD, Kim S, Spritzer KL, et al. Effects of mode and order of administration on generic health-related quality of life scores. Value Health 2009 Sep; 12 (6): 1035–9.
    Paper not yet in RePEc: Add citation now
  54. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, et al. A dynamic population model of disease progression in COPD. Eur Respir J 2005 Aug; 26 (2): 223–33.
    Paper not yet in RePEc: Add citation now
  55. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, et al. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health 2011 Dec; 14 (8): 1039–47.
    Paper not yet in RePEc: Add citation now
  56. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010 Sep; 363 (12): 1128–38.
    Paper not yet in RePEc: Add citation now
  57. Izquierdo JL. The burden of COPD in Spain: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S61–9.
    Paper not yet in RePEc: Add citation now
  58. Jadad AR, To MJ, Emara M, et al. Consideration of multiple chronic diseases in randomized controlled trials. JAMA 2011; 306 (24): 2670–2.
    Paper not yet in RePEc: Add citation now
  59. Jansson SA, Andersson F, Borg S, et al. Costs of COPD in Sweden according to disease severity. Chest 2002 Dec; 122 (6): 1994–2002.
    Paper not yet in RePEc: Add citation now
  60. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
    Paper not yet in RePEc: Add citation now
  61. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med 2001 Aug 1; 164 (3): 358–64.
    Paper not yet in RePEc: Add citation now
  62. Kaplan RM, Atkins CJ, Timms R. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J Chronic Dis 1984; 37 (2): 85–95.
    Paper not yet in RePEc: Add citation now
  63. Kaplan RM, Ries AL, Reilly J, et al. Measurement of health-related quality of life in the National Emphysema Treatment Trial. Chest 2004 Sep; 126 (3): 781–9.
    Paper not yet in RePEc: Add citation now
  64. Kaplan RM. The minimally clinically important difference in generic utility-based measures. COPD 2005 Mar; 2 (1): 91–7.
    Paper not yet in RePEc: Add citation now
  65. Kerstjens HA, Rijcken B, Schouten JP, et al. Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax 1997 Sep; 52 (9): 820–7.
    Paper not yet in RePEc: Add citation now
  66. Kohansal R, Martinez-Camblor P, Agusti A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009 Jul 1; 180 (1): 3–10.
    Paper not yet in RePEc: Add citation now
  67. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003 Apr; 56 (4): 317–25.
    Paper not yet in RePEc: Add citation now
  68. Lee KH, Phua J, Lim TK. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Respir Med 2006 Dec; 100 (12): 2190–6.
    Paper not yet in RePEc: Add citation now
  69. Lin PJ, Shaya FT, Scharf SM. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Respir Med 2010 May; 104 (5): 697–704.
    Paper not yet in RePEc: Add citation now
  70. Lindberg A, Larsson LG, Ronmark E, et al. Co-morbidity in mild-to-moderate COPD: comparison to normal and restrictive lung function. COPD 2011 Dec; 8 (6): 421–8.
    Paper not yet in RePEc: Add citation now
  71. Lock K, Wilson K, Murphy D, et al. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother 2011 Dec; 12 (17): 2613–26.
    Paper not yet in RePEc: Add citation now
  72. Machlin S, Chowdhury S. Expenses and characteristics of physician visits in different ambulatory care settings, 2008. MEPS Statistical Brief #318, March 2011 [online]. Available from URL: http://www.meps.ahrq.gov/mepsweb/data_files/publications/st318/ stat318.pdf [Accessed 2012 Jan 5].
    Paper not yet in RePEc: Add citation now
  73. Mannino DM, Gagnon RC, Petty TL, et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2000 Jun 12; 160 (11): 1683–9.
    Paper not yet in RePEc: Add citation now
  74. Mannino DM, Homa DM, Ford ES, et al. Chronic obstructive pulmonary disease surveillance: United States, 1971–2000. MMWR Surveill Summ 2002 Aug 2; 51 (6): 1–16.
    Paper not yet in RePEc: Add citation now
  75. Mapel DW, Hurley JS, Dalal AA, et al. The role of combination inhaled corticosteroid/long-acting beta-agonist therapy in COPD management. Prim Care Respir J 2010 Jun; 19 (2): 93–103.
    Paper not yet in RePEc: Add citation now
  76. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization. Arch Intern Med 2000 Sep 25; 160 (17): 2653–8.
    Paper not yet in RePEc: Add citation now
  77. Mapel DW, McMillan GP, Frost FJ, et al. Predicting the costs of managing patients with chronic obstructive pulmonary disease. Respir Med 2005 Oct; 99 (10): 1325–33.
    Paper not yet in RePEc: Add citation now
  78. Mapel DW, Picchi MA, Hurley JS, et al. Utilization in COPD: patient characteristics and diagnostic evaluation. Chest 2000 May; 117 (5 Suppl. 2): 346S–53S.
    Paper not yet in RePEc: Add citation now
  79. Mapel DW, Robinson SB, Dastani HB, et al. The direct medical costs of undiagnosed chronic obstructive pulmonary disease. Value Health 2008 Jul–Aug; 11 (4): 628–36.
    Paper not yet in RePEc: Add citation now
  80. Mapel DW, Schum M, Lydick E, et al. A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics 2010; 28 (9): 733–49.
    Paper not yet in RePEc: Add citation now
  81. Marshall DA, Hux M. Design and analysis issues for economic analysis alongside clinical trials. Med Care 2009 Jul; 47 (7 Suppl. 1): S14–20.
    Paper not yet in RePEc: Add citation now
  82. Martinez FJ, Foster G, Curtis JL, et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006 Jun 15; 173 (12): 1326–34.
    Paper not yet in RePEc: Add citation now
  83. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007 May; 62 (5): 411–5.
    Paper not yet in RePEc: Add citation now
  84. McGarvey LP, Magder S, Burkhart D, et al. Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations. Respir Med 2012; 106 (4): 515–21.
    Paper not yet in RePEc: Add citation now
  85. McGhan WF, Al M, Doshi JA, et al. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. Value Health 2009 Nov–Dec; 12 (8): 1086–99.
    Paper not yet in RePEc: Add citation now
  86. Menzin J, Boulanger L, Marton J, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med 2008 Sep; 102 (9): 1248–56.
    Paper not yet in RePEc: Add citation now
  87. Miravitlles M, Llor C, de Castellar R, et al. Validation of the COPD severity score for use in primary care: the NEREA study. Eur Respir J 2009 Mar; 33 (3): 519–27.
    Paper not yet in RePEc: Add citation now
  88. Miravitlles M, Naberan K, Cantoni J, et al. Socioeconomic status and health-related quality of life of patients with chronic obstructive pulmonary disease. Respiration 2011; 82 (5): 402–8.
    Paper not yet in RePEc: Add citation now
  89. Mittmann N, Hernandez P, Mellstrom C, et al. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives. Pharmacoeconomics 2011 May; 29 (5): 403–14.
    Paper not yet in RePEc: Add citation now
  90. Molken MP, Van Doorslaer EK, Rutten FF. Economic appraisal of asthma and COPD care: a literature review 1980–1991. Soc Sci Med 1992 Jul; 35 (2): 161–75.
    Paper not yet in RePEc: Add citation now
  91. Morice AH, Celli B, Kesten S, et al. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010 Nov; 104 (11): 1659–67.
    Paper not yet in RePEc: Add citation now
  92. Moy ML, Reilly JJ, Ries AL, et al. Multivariate models of determinants of health-related quality of life in severe chronic obstructive pulmonary disease. J Rehabil Res Dev 2009; 46 (5): 643–54.
    Paper not yet in RePEc: Add citation now
  93. Mullahy J. Econometric modeling of health care costs and expenditures: a survey of analytical issues and related policy considerations. Med Care 2009 Jul; 47 (7 Suppl. 1): S104–8.
    Paper not yet in RePEc: Add citation now
  94. Naberan K, Azpeitia A, Cantoni J, et al. Impairment of quality of life in women with chronic obstructive pulmonary disease. Respir Med 2012; 106 (3): 367–73.
    Paper not yet in RePEc: Add citation now
  95. Naik S, Kamal KM, Keys PA, et al. Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease. Clinicoecon Outcomes Res 2010; 2: 25–36.
    Paper not yet in RePEc: Add citation now
  96. Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008 Nov; 63 (11): 962–7.
    Paper not yet in RePEc: Add citation now
  97. National Heart, Lung, and Blood Institute. Morbidity & mortality: 2009 chart book on cardiovascular, lung, and blood diseases [online]. Available from URL: http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf [Accessed 2012 Jan 5].
    Paper not yet in RePEc: Add citation now
  98. Neyt M, Devriese S, Thiry N, et al. Tiotropium’s cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions. BMC Pulm Med 2010; 10: 47.
    Paper not yet in RePEc: Add citation now
  99. Nielsen R, Johannessen A, Benediktsdottir B, et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J 2009 Oct; 34 (4): 850–7.
    Paper not yet in RePEc: Add citation now
  100. Oba Y. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care 2009 Apr; 15 (4): 226–32.
    Paper not yet in RePEc: Add citation now
  101. Oostenbrink JB, Rutten-van Molken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005 Jan–Feb; 8 (1): 32–46.
    Paper not yet in RePEc: Add citation now
  102. Patel AR, Donaldson GC, Mackay AJ, et al. The impact of ischemic heart disease on symptoms, health status and exacerbations in COPD. Chest 2012 Apr; 141 (4): 851–7.
    Paper not yet in RePEc: Add citation now
  103. Pichon-Riviere A, Augustovski F, Bardach A, et al. Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America. Value Health 2011 Jul–Aug; 14 (5 Suppl. 1): S51–9.
    Paper not yet in RePEc: Add citation now
  104. Piperno D, Huchon G, Pribil C, et al. The burden of COPD in France: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S33–42.
    Paper not yet in RePEc: Add citation now
  105. Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med 2011 Nov; 105 (11): 1635–47.
    Paper not yet in RePEc: Add citation now
  106. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005 Sep–Oct; 8 (5): 521–33.
    Paper not yet in RePEc: Add citation now
  107. Ramsey SD, Berry K, Etzioni R, et al. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 2003 May 22; 348 (21): 2092–102.
    Paper not yet in RePEc: Add citation now
  108. Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl 2003 Jun; 41: 29s–35s.
    Paper not yet in RePEc: Add citation now
  109. Ramsey SD. Suboptimal medical therapy in COPD: exploring the causes and consequences. Chest 2000 Feb; 117 (2 Suppl.): 33S–7S.
    Paper not yet in RePEc: Add citation now
  110. Ringbaek T, Brondum E, Martinez G, et al. EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients. Respir Med 2008 Nov; 102 (11): 1563–7.
    Paper not yet in RePEc: Add citation now
  111. Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19 (6): 623–42.
    Paper not yet in RePEc: Add citation now
  112. Rutten-van Molken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006 Sep; 3 (7): 630–4.
    Paper not yet in RePEc: Add citation now
  113. Rutten-van Molken MP, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics 2009; 27 (6): 465–77.
    Paper not yet in RePEc: Add citation now

  114. Rutten-van Molken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007 Jun; 8 (2): 123–35.

  115. Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006 Oct; 130 (4): 1117–28.
    Paper not yet in RePEc: Add citation now
  116. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000 May; 161 (5): 1608–13.
    Paper not yet in RePEc: Add citation now
  117. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005 Mar; 43 (3): 203–20.
    Paper not yet in RePEc: Add citation now
  118. Silverman EK. Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression? Proc Am Thorac Soc 2007 Dec; 4 (8): 586–90.
    Paper not yet in RePEc: Add citation now
  119. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004 Mar 1; 116 (5): 325–31.
    Paper not yet in RePEc: Add citation now
  120. Soni A. Top 10 most costly conditions among men and women, 2008: estimates for the U.S. civilian non-institutionalized adult population, age 18 and older. MEPS Statistical Brief #331, July 2011 [online]. Available from URL: http://www.meps.ahrq.gov/mepsweb/data_files/publications/st331/ stat331.shtml [Accessed 2012 Jan 5].
    Paper not yet in RePEc: Add citation now

  121. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23 (6): 619–37.

  122. Stahl E, Jansson SA, Jonsson AC, et al. Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD. Health Qual Life Outcomes 2003; 1: 18.
    Paper not yet in RePEc: Add citation now
  123. Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for the future. Int J Chron Obstruct Pulmon Dis 2008; 3 (1): 71–88.
    Paper not yet in RePEc: Add citation now
  124. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA 1989 Aug 18; 262 (7): 907–13.
    Paper not yet in RePEc: Add citation now
  125. Sun SX, Marynchenko M, Banerjee R, et al. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J Med Econ 2011; 14 (6): 805–15.
    Paper not yet in RePEc: Add citation now
  126. Tinkelman D, Nordyke RJ, Isonaka S, et al. The impact of chronic obstructive pulmonary disease on long-term disability costs. J Manag Care Pharm 2005 Jan–Feb; 11 (1): 25–32.
    Paper not yet in RePEc: Add citation now
  127. Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003 Sep; 22 (3): 462–9.
    Paper not yet in RePEc: Add citation now
  128. van den Boom G, Rutten-van Molken MP, Molema J, et al. The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease: results of the DIMCA program. Am J Respir Crit Care Med 2001 Dec 1; 164 (11): 2057–66.
    Paper not yet in RePEc: Add citation now
  129. van der Palen J, Monninkhof E, van der Valk P, et al. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease. Thorax 2006 Jan; 61 (1): 29–33.
    Paper not yet in RePEc: Add citation now
  130. Van Wave TW, Scutchfield FD, Honore PA. Recent advances in public health systems research in the United States. Annual review of public health, vol. 31. Palo Alto (CA): Annual Reviews, 2010: 283–95.
    Paper not yet in RePEc: Add citation now
  131. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008 Apr; 31 (4): 869–73.
    Paper not yet in RePEc: Add citation now
  132. Workshop report: 2005 update. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease [online]. Available from URL: http://goldcopd.org/guidelines-global-strategy-for-diagnosis-ma nagement.html [Accessed 2012 Jan 5].
    Paper not yet in RePEc: Add citation now
  133. Worth H, Chung KF, Felser JM, et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011 Apr; 105 (4): 571–9.
    Paper not yet in RePEc: Add citation now
  134. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003 Mar; 97 Suppl. C: S3–14.
    Paper not yet in RePEc: Add citation now
  135. Wouters EF. The burden of COPD in the Netherlands: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl. C: S51–9.
    Paper not yet in RePEc: Add citation now

  136. Zaniolo O, Iannazzo S, Pradelli L, et al. Pharmaco-economic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. Eur J Health Econ 2012; 13 (1): 71–80.

  137. Zaniolo O, Iannazzo S, Pradelli L, et al. Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. Eur J Health Econ 2012 Feb; 13 (1): 71–80.
    Paper not yet in RePEc: Add citation now

Cocites

Documents in RePEc which have cited the same bibliography

  1. Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions. (2021). Lewis, Ruth A ; Hughes, Dyfrig ; Wilkinson, Clare ; Sutton, Alex J.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:39:y:2021:i:1:d:10.1007_s40273-020-00980-w.

    Full description at Econpapers || Download paper

  2. A Framework for Developing a Model Structure of Budget Impact Analysis for New Health Care Interventions in Jordan. (2021). Massad, Eman Mohammad ; Bakir, Amir.
    In: International Journal of Economics and Financial Issues.
    RePEc:eco:journ1:2021-01-13.

    Full description at Econpapers || Download paper

  3. A Systematic Review of Model-Based Economic Evaluations of Treatments for Venous Leg Ulcers. (2020). Levell, N J ; McManus, Emma ; Layer, Ashley.
    In: PharmacoEconomics - Open.
    RePEc:spr:pharmo:v:4:y:2020:i:2:d:10.1007_s41669-019-0148-x.

    Full description at Econpapers || Download paper

  4. Modelling the impact of physical activity on public health: A review and critique. (2020). Candio, Paolo ; Bojke, Laura ; Meads, David ; Hill, Andrew J.
    In: Health Policy.
    RePEc:eee:hepoli:v:124:y:2020:i:10:p:1155-1164.

    Full description at Econpapers || Download paper

  5. Spatial Transmission Models: A Taxonomy and Framework. (2019). Robertson, Duncan A.
    In: Risk Analysis.
    RePEc:wly:riskan:v:39:y:2019:i:1:p:225-243.

    Full description at Econpapers || Download paper

  6. Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review. (2019). Newman, William G ; Wright, Stuart J ; Payne, Katherine.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:37:y:2019:i:8:d:10.1007_s40273-019-00801-9.

    Full description at Econpapers || Download paper

  7. Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany. (2019). Schneider, Udo ; Holle, Rolf ; Laxy, Michael ; Kahm, Katharina.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:37:y:2019:i:1:d:10.1007_s40273-018-0699-1.

    Full description at Econpapers || Download paper

  8. A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments. (2019). Cranmer, Holly L ; Shields, Gemma E ; Bullement, Ash.
    In: Applied Health Economics and Health Policy.
    RePEc:spr:aphecp:v:17:y:2019:i:6:d:10.1007_s40258-019-00513-3.

    Full description at Econpapers || Download paper

  9. Smoking Cessation: A Comparison of Two Model Structures. (2018). Taylor, Matthew ; Owen, Lesley ; Pennington, Becky ; Filby, Alex.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:36:y:2018:i:9:d:10.1007_s40273-018-0657-y.

    Full description at Econpapers || Download paper

  10. The Use of Decision–Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal. (2018). Sach, Tracey ; Levell, Nick ; McManus, Emma.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:36:y:2018:i:1:d:10.1007_s40273-017-0564-7.

    Full description at Econpapers || Download paper

  11. Model Structuring for Economic Evaluations of New Health Technologies. (2018). Bojke, Laura ; Karnon, Jonathan ; Ali, Hossein Haji.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:36:y:2018:i:11:d:10.1007_s40273-018-0693-7.

    Full description at Econpapers || Download paper

  12. Model Registration: A Call to Action. (2017). Sampson, Christopher ; Wrightson, Tim.
    In: PharmacoEconomics - Open.
    RePEc:spr:pharmo:v:1:y:2017:i:2:d:10.1007_s41669-017-0019-2.

    Full description at Econpapers || Download paper

  13. Simulation Modelling in Healthcare: An Umbrella Review of Systematic Literature Reviews. (2017). Salleh, Syed ; Hughes, Ruby ; Thokala, Praveen ; Booth, Andrew ; Brennan, Alan.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:35:y:2017:i:9:d:10.1007_s40273-017-0523-3.

    Full description at Econpapers || Download paper

  14. Using Parameter Constraints to Choose State Structures in Cost-Effectiveness Modelling. (2017). Welton, Nicky ; Sharples, Linda ; Thom, Howard ; Jackson, Chris.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:35:y:2017:i:9:d:10.1007_s40273-017-0501-9.

    Full description at Econpapers || Download paper

  15. Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. (2017). Shih, Ya-Chen ; Lecomte, Pascal ; Olson, Melvin ; Mullins, Daniel C ; Goto, Daisuke ; Udeze, Chukwukadibia ; Park, Yujin.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:35:y:2017:i:7:d:10.1007_s40273-017-0505-5.

    Full description at Econpapers || Download paper

  16. Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care. (2017). Brazier, John ; Azzabi-Zouraq, Ismail ; Chevrou-Severac, Helene ; Rowen, Donna ; Mukuria, Clara ; Hout, Ben ; Young, Tracey ; Peasgood, Tessa ; Paisley, Suzy ; Ara, Roberta.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:35:y:2017:i:1:d:10.1007_s40273-017-0543-z.

    Full description at Econpapers || Download paper

  17. An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting. (2017). Scuffham, Paul ; Comans, T A ; Standfield, L B.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:18:y:2017:i:1:d:10.1007_s10198-015-0756-z.

    Full description at Econpapers || Download paper

  18. Enabling better management of patients: discrete event simulation combined with the STAR approach. (2017). Demir, Eren ; Southern, David.
    In: Journal of the Operational Research Society.
    RePEc:pal:jorsoc:v:68:y:2017:i:5:d:10.1057_s41274-016-0029-y.

    Full description at Econpapers || Download paper

  19. Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease. (2016). Santos, Rodrigo Dos ; Hernandez, Luis ; Getsios, Denis ; Ozen, Asli .
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:7:d:10.1007_s40273-016-0392-1.

    Full description at Econpapers || Download paper

  20. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. (2016). Wasem, Juergen ; Beutels, Philippe ; Levy-Bruhl, Daniel ; Damm, Oliver ; Ultsch, Bernhard ; Wichmann, Ole ; Bruggenjurgen, Bernd ; Knol, Mirjam ; Gerber-Grote, Andreas ; Perleth, Matthias ; Kuhlmann, Alexander ; Jit, Mark ; Postma, Maarten ; Greiner, Wolfgang ; Siebert, Uwe ; Bilcke, Joke ; Kries, Rudiger ; Salo, Heini ; Hutubessy, Raymond ; Hanquet, Germaine .
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:3:p:227-244.

    Full description at Econpapers || Download paper

  21. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. (2016). Wasem, Juergen ; Beutels, Philippe ; Levy-Bruhl, Daniel ; Damm, Oliver ; Ultsch, Bernhard ; Wichmann, Ole ; Bruggenjurgen, Bernd ; Knol, Mirjam ; Gerber-Grote, Andreas ; Perleth, Matthias ; Kuhlmann, Alexander ; Jit, Mark ; Postma, Maarten ; Greiner, Wolfgang ; Siebert, Uwe ; Bilcke, Joke ; Kries, Rudiger ; Salo, Heini ; Hutubessy, Raymond ; Hanquet, Germaine .
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:3:d:10.1007_s40273-015-0335-2.

    Full description at Econpapers || Download paper

  22. Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment. (2016). Card, Timothy ; West, Joe ; Canavan, Caroline.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:2:p:181-194.

    Full description at Econpapers || Download paper

  23. Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment. (2016). Card, Timothy ; West, Joe ; Canavan, Caroline.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:2:d:10.1007_s40273-015-0339-y.

    Full description at Econpapers || Download paper

  24. Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations. (2016). Rogowski, Wolf H ; Payne, Katherine ; Iglesias, Cynthia P ; Thompson, Alexander.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:11:d:10.1007_s40273-016-0425-9.

    Full description at Econpapers || Download paper

  25. A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure. (2016). Tomini, F ; Prinzen, F.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:17:y:2016:i:9:d:10.1007_s10198-015-0752-3.

    Full description at Econpapers || Download paper

  26. Calibrating Parameters for Microsimulation Disease Models. (2016). Lansdorp-Vogelaar, Iris ; de Koning, Harry J ; van Hees, Frank ; Steyerberg, Ewout W ; van der Steen, Alex ; Kroep, Sonja ; van Ballegooijen, Marjolein ; van Rosmalen, Joost.
    In: Medical Decision Making.
    RePEc:sae:medema:v:36:y:2016:i:5:p:652-665.

    Full description at Econpapers || Download paper

  27. Incorporating Psychological Predictors of Treatment Response into Health Economic Simulation Models. (2015). Basarir, Hasan ; Kruger, Jen ; Cooke, Debbie ; Pollard, Daniel ; Brennan, Alan ; Heller, Simon ; Bond, Rod ; Thokala, Praveen ; Clark, Marie.
    In: Medical Decision Making.
    RePEc:sae:medema:v:35:y:2015:i:7:p:872-887.

    Full description at Econpapers || Download paper

  28. Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Lymphocytic Leukaemia: A Review of Methods to Model Disease Outcomes and Estimate Utility. (2014). Xu, Peng ; Orfanos, Panagiotis ; Marsh, Kevin ; Gordon, James ; Griebsch, Ingolf.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:32:y:2014:i:10:p:981-993.

    Full description at Econpapers || Download paper

  29. Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model. (2014). Severens, Johan ; Knottnerus, J. ; Ramos, G. ; Dompeling, Edward ; Asselt, Antoinette ; Maas, Tanja ; Kuiper, Sandra ; Schayck, Onno .
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:15:y:2014:i:8:p:869-883.

    Full description at Econpapers || Download paper

  30. A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder. (2014). Mohiuddin, Syed.
    In: Applied Health Economics and Health Policy.
    RePEc:spr:aphecp:v:12:y:2014:i:4:p:359-372.

    Full description at Econpapers || Download paper

  31. Combining discrete-event simulation and system dynamics in a healthcare setting: A composite model for Chlamydia infection. (2014). Harindra, V. ; Brailsford, S. C. ; Harper, P. R. ; Viana, J..
    In: European Journal of Operational Research.
    RePEc:eee:ejores:v:237:y:2014:i:1:p:196-206.

    Full description at Econpapers || Download paper

  32. Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling. (2013). Gray, Alastair ; Fonseca, Tiago ; Baldwin, Michael ; Mungapen, Laura ; Price, David ; Asukai, Yumi.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:31:y:2013:i:2:p:151-161.

    Full description at Econpapers || Download paper

  33. Improving Health Outcomes Through Better Capacity Allocation in a Community-Based Chronic Care Model. (2013). Jiang, Tingting ; Samuelson, Stephen ; Iravani, Seyed ; Deo, Sarang ; Smilowitz, Karen.
    In: Operations Research.
    RePEc:inm:oropre:v:61:y:2013:i:6:p:1277-1294.

    Full description at Econpapers || Download paper

  34. Economic implications of poor access to antenatal care in rural and remote Western Australian Aboriginal communities: An individual sampling model of pregnancy. (2013). Simmer, Karen ; Newnham, John P. ; Cannon, Jeffrey W. ; Hornbuckle, Janet ; Doherty, Dorota A. ; Larson, Ann ; Mueller, Ute A..
    In: European Journal of Operational Research.
    RePEc:eee:ejores:v:226:y:2013:i:2:p:313-324.

    Full description at Econpapers || Download paper

  35. Modeling Using Discrete Event Simulation. (2012). Karnon, Jonathan ; Mar, Javier ; Stahl, James ; Caro, Jaime J ; Brennan, Alan ; Mller, Jrgen.
    In: Medical Decision Making.
    RePEc:sae:medema:v:32:y:2012:i:5:p:701-711.

    Full description at Econpapers || Download paper

  36. Modeling Good Research Practices€”Overview. (2012). Siebert, Uwe ; Kuntz, Karen M ; Caro, Jaime J ; Briggs, Andrew H.
    In: Medical Decision Making.
    RePEc:sae:medema:v:32:y:2012:i:5:p:667-677.

    Full description at Econpapers || Download paper

  37. Future Impact of Various Interventions on the Burden of COPD in Canada: A Dynamic Population Model. (2012). Fitzgerald, Mark J ; Lynd, Larry D ; Sin, Don ; Marra, Carlo A ; McManus, Bruce ; Sadatsafavi, Mohsen ; Najafzadeh, Mehdi.
    In: PLOS ONE.
    RePEc:plo:pone00:0046746.

    Full description at Econpapers || Download paper

  38. Resource planning for ambulance services in mass casualty incidents: a DES-based policy model. (2012). Schaffhauser-Linzatti, Michaela ; Rauner, Marion ; Niessner, Helmut.
    In: Health Care Management Science.
    RePEc:kap:hcarem:v:15:y:2012:i:3:p:254-269.

    Full description at Econpapers || Download paper

  39. What happens to value of information measures as the number of decision options increases?. (2011). Barton, Pelham.
    In: Health Economics.
    RePEc:wly:hlthec:v:20:y:2011:i:7:p:853-863.

    Full description at Econpapers || Download paper

  40. A Framework for Addressing Structural Uncertainty in Decision Models. (2011). Thompson, Simon G ; Sharples, Linda D ; Bojke, Laura ; Claxton, Karl ; Jackson, Christopher H.
    In: Medical Decision Making.
    RePEc:sae:medema:v:31:y:2011:i:4:p:662-674.

    Full description at Econpapers || Download paper

  41. Dynamic versus static models in cost‐effectiveness analyses of anti‐viral drug therapy to mitigate an influenza pandemic. (2010). Mylius, Sido D. ; Wallinga, Jacco ; Lugner, Anna K..
    In: Health Economics.
    RePEc:wly:hlthec:v:19:y:2010:i:5:p:518-531.

    Full description at Econpapers || Download paper

  42. Hospital management games: a taxonomy and extensive review. (2010). Schwarz, Sigrun ; Kraus, Markus ; Rauner, Marion.
    In: Central European Journal of Operations Research.
    RePEc:spr:cejnor:v:18:y:2010:i:4:p:567-591.

    Full description at Econpapers || Download paper

  43. Reducing access times for an endoscopy department by an iterative combination of computer simulation and Linear Programming. (2010). Elkhuizen, S. ; Joustra, P. ; Fockens, P. ; Wit, J. ; Overbeek, B. ; Struben, V..
    In: Health Care Management Science.
    RePEc:kap:hcarem:v:13:y:2010:i:1:p:17-26.

    Full description at Econpapers || Download paper

  44. Dynamic Policy Modeling for Chronic Diseases: Metaheuristic-Based Identification of Pareto-Optimal Screening Strategies. (2010). Gutjahr, Walter J ; Rauner, Marion S ; Heidenberger, Kurt ; Pasia, Joseph ; Wagner, Joachim.
    In: Operations Research.
    RePEc:inm:oropre:v:58:y:2010:i:5:p:1269-1286.

    Full description at Econpapers || Download paper

  45. Simulation sample sizes for Monte Carlo partial EVPI calculations. (2010). Tappenden, Paul ; Chilcott, Jim ; Oakley, Jeremy E. ; Brennan, Alan.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:29:y:2010:i:3:p:468-477.

    Full description at Econpapers || Download paper

  46. Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness. (2010). Soares, Marta ; L Canto e Castro, .
    In: Working Papers.
    RePEc:chy:respap:56cherp.

    Full description at Econpapers || Download paper

  47. The cost-effectiveness of surgical instrument management policies to reduce the risk of vCJD transmission to humans. (2009). Chick, S E ; Stevenson, M D ; Chalkidou, K ; Oakley, J E.
    In: Journal of the Operational Research Society.
    RePEc:pal:jorsoc:v:60:y:2009:i:4:d:10.1057_palgrave.jors.2602580.

    Full description at Econpapers || Download paper

  48. A tutorial on discrete-event simulation for health policy design and decision making: Optimizing pediatric ultrasound screening for hip dysplasia as an illustration. (2009). Sakkers, Ralph J. B., ; Ramwadhdoebe, Sabrina ; Stahl, James E. ; Buskens, Erik.
    In: Health Policy.
    RePEc:eee:hepoli:v:93:y:2009:i:2-3:p:143-150.

    Full description at Econpapers || Download paper

  49. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. (2007). Stevenson, Matt ; Madan, Jason ; O'Hagan, Anthony.
    In: Health Economics.
    RePEc:wly:hlthec:v:16:y:2007:i:10:p:1009-1023:a.

    Full description at Econpapers || Download paper

  50. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. (2007). Stevenson, Matt ; Madan, Jason ; O'Hagan, Anthony.
    In: Health Economics.
    RePEc:wly:hlthec:v:16:y:2007:i:10:p:1009-1023.

    Full description at Econpapers || Download paper

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2025-09-21 21:40:07 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated August, 3 2024. Contact: Jose Manuel Barrueco.